| Outcome Measures: |
Primary: Mean change in HbA1c from baseline to week 24, Baseline to Week 24 | Secondary: Mean change in HbA1c from baseline to week 12 and week 36, Baseline to Week 12 and 36|Percentage of participants achieving HbA1c target <7%, at Week 12, 24 and 36|Percentage of participants achieving HbA1c target <7% without hypoglycemic events, at Week 12 and 24|Mean change in Fasting Plasma Glucose (FPG) from baseline to week 12, 24 and 36, Baseline to Week 12, 24 and 36|Mean change in fasting Self-Monitored Blood Glucose (SMBG) from baseline to week 12 and week 24, Baseline to Week 12 and 24|Mean change in of 7-points SMBG per time point from baseline to week 12 and week 24, Baseline to Week 12 and 24|Mean change in Insulin glargine U300 dose from baseline to week 12, 24 and 36, Baseline to Week 12, 24 and 36|Number of participants experiencing hypoglycemia from baseline to week 12, 24 and 36, Baseline to Week 12, 24 and 36|Number of hypoglycemic events per patient-year, Baseline to Week 12, 24 and 36|Number of participants with adverse events, Baseline to Week 24 and 36|Mean change in body weight from baseline to Week 12 and Week 24, Baseline to Week 12 and 24
|
